DDInter973 DDInter1435
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Irinotecan {u} (Compound) treats {v} (Disease) hematologic cancer
Irinotecan {u} (Compound) binds {v} (Gene) ABCC1
Irinotecan {u} (Compound) upregulates {v} (Gene) PHLDA3
Irinotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Irinotecan {u} (Compound) downregulates {v} (Gene) PCMT1
Irinotecan {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Verapamil
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Irinotecan (Compound) treats hematologic cancer (Disease)
Irinotecan (Compound) binds ABCC1 (Gene)
Irinotecan (Compound) upregulates PHLDA3 (Gene)
Irinotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Irinotecan (Compound) downregulates PCMT1 (Gene)
Irinotecan (Compound) causes Febrile neutropenia (Side Effect)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Verapamil